| 三阴性乳腺癌的分子生物学及治疗进展 |
| |
| 引用本文： | 刘俊杰,钱军. 三阴性乳腺癌的分子生物学及治疗进展[J]. 国际肿瘤学杂志, 2016, 0(7): 526-528. DOI: 10.3760/cma.j.issn.1673-422X.2016.07.011 |
| |
| 作者姓名： | 刘俊杰 钱军 |
| |
| 作者单位： | 233004,蚌埠医学院第一附属医院肿瘤外三科 |
| |
| 摘 要： | 三阴性乳腺癌（TNBC）难以获益于内分泌治疗或曲妥珠单抗靶向药物治疗，乳腺癌易感基因1、p53基因、血管内皮生长因子、微小 RNA 等的生物过表达提示其易转移复发和较差的预后。探索 TNBC 的分子亚型、制定针对亚分类的治疗方案、寻找相应单克隆抗体的靶点是今后的研究方向。
|
| 关 键 词： | 乳腺肿瘤 分子生物学 基因 治疗 |
Progress of molecular biology and treatment for triple negative breast cancer |
| |
| Abstract: | Triple negative breast cancer (TNBC)is difficult to benefit from endocrine therapy or tras-tuzumab targeted drug therapy.Biological overexpression of breast cancer susceptibility gene 1,p53 gene,vas-cular endothelial growth factor and microRNA suggests that TNBC is easy to metastasis and recurrence and has a poor prognosis.Exploring the molecular subtypes of TNBC,setting out the treatment plan for subtypes and finding the corresponding monoclonal antibody targets are the research direction of TNBC in the future. |
| |
| Keywords: | Breast neoplasms Molecular biology Genes Therapy |
| 本文献已被 万方数据 等数据库收录！ |
|
